The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Investigating the barriers to participation in clinical trials in AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses the main findings of a study investigating the barriers to amyloidosis clinical trial participation. Across patients with light chain (AL) amyloidosis enrolled in trials at the Boston University Amyloidosis Center between 1994 and 2023, 11% were from racial/ethnic minorities, highlighting a clear need for more diversity. Additionally, only 39% of patients screened in the past five years went on to participate in trials, with Dr Sanchorawala highlighting the main reasons for this. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Support/P.I. Celgene, Millennium-Takeda, Janssen, Prothena, Sorrento, Karyopharm, Oncopeptide, Caelum, Alexion
Consultant Pfizer, Janssen, Attralus, GateBio, Abbvie
Scientific Advisory Board Proclara, Caelum, Abbvie, Janssen, Regeneron, Protego, Pharmatrace, Telix, Prothena, AstraZeneca, Nexcella
